

## December 2nd

**10:00-10:15:** Opening Remarks

### 1. Session Biomarkers in neurodegenerative disease

**10:15-11:00:** Novel fluid biomarkers in Alzheimer's disease

**Albert Lleó**  
*University of Barcelona*

**11:00-11:30:** Coffee break

**11:30-12:15:** Non-productive angiogenesis in Alzheimer's disease:  
a tale of three friends

**Alberto Pascual**  
*Instituto de Biomedicina de Sevilla (IBiS)*

**12:15-13:00:** Roundtable **Clinical and fundamental research  
integration**

**13:00 -14:00** Lunch break

### 2. Session Emerging pathomechanisms

**14:00-14:45** Innate immunity cause or consequence of  
neurodegeneration?

**Michael T. Heneka**  
*University of Bonn*

**14:45-15:30** Neurogenetic Signatures of Neurodegeneration  
Across Brain Networks

**Jorge Sepulcre**  
*Harvard Medical School*

**15:30-16:00** Coffee break

**16:00-16:45** T cell immunity in the pathophysiology of Alzheimer's  
disease and Tauopathies

**Guillaume Dorothée**  
*INSERM UMRS 938, University of Paris*

## December 3rd

### 3. Session Risk factors: glia and vascular implications

**10:00-10:45** Mechanisms of neurodegeneration from phenotype to  
molecular diagnosis

**Merce Boada**  
*Fundacio ACE*

**10:45-11:30** Reactive astrocytes in Alzheimer's disease pathogenesis

**Antonia Gutierrez**  
*University of Malaga*

**11:30-12:00** Coffee break

**12:00-12:45** CSF proteomics strategies to uncover disease mechanisms  
in dementias

**Charlotte Theunissen**  
*University of Amsterdam*

**12:45-13:30** Roundtable **Advice and perspectives for students and  
young scientists pursuing a scientific career**

**13:30 -15:00** Lunch break

**15:00-16:00** Plenary Lecture/ Uncovering the role of Alzheimer's  
disease risk genes using stem cells and human brains

**Li-Huei Tsai**  
*Massachusetts Institute of Technology (USA)*

**16:00-16:30** Final conclusions

At this time, there is no cure for any neurodegenerative disease. Most treatments are limited in effect and mainly address the symptoms rather than the cause or the progressive course. The lack of any effective treatment stems from a scarcity of novel drug targets and a poor understanding of diseases biology. In addition, a successful treatment at late stages, when the integrity of the nervous tissue is highly compromised, is very unlikely.

The goal of this meeting (with the collaboration of CIBERNED, ISCIII) would be to bring together international and national leading scientists to present the most recent advances in the field. The community of basic and translational scientists will provide an ideal opportunity to debate about how the achievements in this area can lead to design new therapeutic approaches for these pathologies.

Lugar de celebración:

Instituto de Biomedicina  
de Sevilla (IBiS)  
Campus HUVR  
Avenida Manuel Siurot s/n  
41013. Sevilla

Modalidad semipresencial

Tarifa del curso 1: **115 € Modalidad presencial**

Tarifa del curso 2: **115 € menos 50% descuento. Modalidad on-line**

\*Los alumnos que acrediten estar matriculados en estudios conducentes a la obtención de un título de Grado o Doctor en una universidad española, tendrán un **20% de descuento en el precio de la matrícula**

**Tasa apertura expediente académico 20 €**

Esta tasa se aplicará a los alumnos al momento de la formalización de la matrícula

Información Matrículas:

UIMP  
Patio de Banderas 9  
41004 Sevilla  
Tfno: 954-228731 954-212396

[www.uimp.es](http://www.uimp.es)



**UIMP** Universidad Internacional  
Menéndez Pelayo

# VI UIMP-IBIS SCHOOL OF BIOMEDICINE MECHANISMS OF NEURODEGENERATION: from genes to neural networks

Seville, December 2nd and 3rd, 2021

Directores:

**Javier Vitorica Ferrández**  
*IBiS, University of Seville*  
**Michael Heneka**  
*University of Bonn*

**UIMP**  
**SEVILLA**  
**OTOÑO 2021**

**UIMP** Universidad Internacional  
Menéndez Pelayo

Colabora



**IBiS**  
INSTITUTO DE BIOMEDICINA DE SEVILLA